The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...

Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Fostemsavir plus optimized background therapy was associated with improvements in immune biomarkers among HTE patients with MDR HIV infection.

Maharashtra launches a groundbreaking 28-day TB treatment for HIV patients aiming to reduce mortality and improve healthcare ...

Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...

A new study published in the Journal of Clinical Tuberculosis and Other Mycobacterial Diseases showed that two ...